Michael A Fishman1, Phillip S Kim2. 1. Center for Interventional Pain and Spine, Wilmington, DE, USA. MFishman@centerisp.com. 2. Center for Interventional Pain and Spine, Wilmington, DE, USA.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of buprenorphine in the treatment of chronic pain. RECENT FINDINGS: There has been few high-quality, unbiased studies performed on the use of buprenorphine in the treatment of chronic pain. Buprenorphine is an effective and safe analgesic that is tolerated at least as well, if not better, than other opioids. Given its safety and mechanistic advantages, the authors believe there is an important role for buprenorphine in the treatment of chronic pain severe enough to warrant the use of an opioid analgesic. Though data is lacking for superiority in chronic pain states, the other advantages of the molecule make it the preferential first-line opioid for around-the-clock pain in our practice.
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of buprenorphine in the treatment of chronic pain. RECENT FINDINGS: There has been few high-quality, unbiased studies performed on the use of buprenorphine in the treatment of chronic pain. Buprenorphine is an effective and safe analgesic that is tolerated at least as well, if not better, than other opioids. Given its safety and mechanistic advantages, the authors believe there is an important role for buprenorphine in the treatment of chronic pain severe enough to warrant the use of an opioid analgesic. Though data is lacking for superiority in chronic pain states, the other advantages of the molecule make it the preferential first-line opioid for around-the-clock pain in our practice.
Authors: Allan Gordon; Denis Callaghan; Donald Spink; Christian Cloutier; Peter Dzongowski; William O'Mahony; Duncan Sinclair; Saifudin Rashiq; Norm Buckley; Geoffrey Cohen; James Kim; Aline Boulanger; Paula S Piraino; John Eisenhoffer; Zoltan Harsanyi; Andrew C Darke; Kenneth J Michalko Journal: Clin Ther Date: 2010-05 Impact factor: 3.393
Authors: Aaron Yarlas; Kate Miller; Warren Wen; Shau Yu Lynch; Steven R Ripa; Joseph V Pergolizzi; Robert B Raffa Journal: Pain Pract Date: 2015-01-20 Impact factor: 3.183
Authors: D Andrew Tompkins; Michael T Smith; Miriam Z Mintzer; Claudia M Campbell; Eric C Strain Journal: J Pharmacol Exp Ther Date: 2013-11-13 Impact factor: 4.030
Authors: Pooja Lagisetty; Alex Smith; Derek Antoku; Suzanne Winter; Michael Smith; Mary Jannausch; Hae Mi Choe; Amy S B Bohnert; Michele Heisler Journal: Am J Health Syst Pharm Date: 2020-05-07 Impact factor: 2.637
Authors: Suhani Dalal; Ahish Chitneni; Amnon A Berger; Vwaire Orhurhu; Bilal Dar; Bennett Kramer; Anvinh Nguyen; John Pruit; Charles Halsted; Alan D Kaye; Jamal Hasoon Journal: Health Psychol Res Date: 2021-08-06